摘要
目的 通过测定应用促性腺激素释放激素激动剂 (GnRH A)后子宫肌瘤病理改变及增殖细胞核抗原水平变化 ,探讨GnRH A在治疗子宫肌瘤中的作用。 方法 子宫肌瘤术后标本 33例 ,术前应用GnRH A 18例为用药组 ,对照组 15例 ,常规病理检查 ,并用免疫组织化学 (ABC)方法检测增殖细胞核抗原 (PCNA)的含量。 结果 肌瘤组织变性率及免疫组织化学测定PCNA变化两组无明显差异 ,计算机图像分析表明用药后肌瘤细胞体积及间质有明显缩小 (P <0 0 5 )。 结论 本实验证实GnRH A治疗子宫肌瘤 ,肌瘤缩小与肌瘤细胞体积及间质缩小有关 ,停药后易复发 。
Objective To investigate the expression of proliferating cell nuclear antigen (PCNA) and histological findings of uterine leiomyomas after gonadotropin releasing hormone agonist (GnRH A) treatment in the uterine leiomyomas before hysterectomy, and to assess the therapeutic effects of GnRH agonist on uterine leiomyomas Methods A total of 33 uterine leiomyomas were divided into treated group (18) and control group (15) PCNA expression in the leiomyomas was determined with immunohistochemistry (ABC method) Results The occurrence of hyaline degeneration and PCNA expression in the leiomyomas had no significant difference between the GnRH A treated group and control group. Data of image analyser system (IAS) showed that the reduction in myoma volume with GnRH A agonist therapy was associated with reducing in extracellular matrix and cellular volume. Conclusions GnRH A treatment reduces the leiomyoma volume, which is associated with reducing in extracellular matrix and cellular volume Although the tumor may reoccur after treatment, it is a good method to be used before hysterectomy
出处
《总装备部医学学报》
2004年第1期4-5,共2页
Medical Journal of General Equipment Headquarters
关键词
子宫肌瘤
促性腺激素释放激素激动剂
病理
增殖细胞核抗原
Uterine leiomyoma Gonadotropin-releasing hormone agonist Pathology Proliferating cell nuclear antigen(PCNA)
